| Revenue growth | Q2 +30% YoY; H1 +19% YoY. |
|---|---|
| Margins | Q2 gross margin 35% (+268bps YoY); EBITDA margin 21% (+145bps). |
| Demand visibility | Volume-led growth; 88% revenue from regulated markets. |
| Management confidence | FY27 revenue and EBITDA margin now expected above earlier guidance. |
Growth
Q2 revenue ₹316 Cr (+30%), EBITDA ₹68 Cr (+40%), PAT ₹40 Cr (+57%). H1 revenue ₹523 Cr (+19%).
Outlook
₹280 Cr capex by FY27; 10 DMF/CEP filings targeted FY27; FY27 growth and margins to beat guidance.
Risks
China raw-material dependency (rated 'Low'); generics price erosion; asset turnover still 1.46x.
Last quarter's promises, checked
Delivered
- FY27 revenue growth guided 15% → H1 +19% YoY, H1 only (= BEAT)
- FY27 EBITDA margin to improve on FY26's 20% → Q2 21% (= BEAT)
Partly delivered
- FY27 EBITDA margin ~22% → Q2 21% (= PARTIAL)
- 10 DMF/CEP filings in FY27 → 6 filed by H1 (= PARTIAL, on pace)
- ₹280 Cr capex by FY27 (₹130 Cr spent by May-26) → reiterated, no spend update (= PARTIAL)
Investor Presentation filed with NSE, NSE: SMSPHARMA. Summary written with AI assistance from the document.
SMS Pharmaceuticals Ltd: key numbers
- Share price
- ₹524.90
- Market cap
- ₹4,653 Cr
- Revenue (annual)
- ₹886.9 Cr
- Net profit (annual)
- ₹102.0 Cr
- P/E (TTM)
- 45.4×Sector 41.3×
- Promoter holding
- 68.07%+0.00% QoQ
- FII holding
- 1.18%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from SMS Pharmaceuticals Ltd
All →SMS Pharmaceuticals Results Update
SMS Pharmaceuticals released a press release on its Q2 and H1 FY27 results, showing strong growth. Management now expects FY27 revenue growth and EBITDA margins above earlier guidance.
SMS Pharmaceuticals Management Change
SMS Pharmaceuticals' Company Secretary Thirumalesh Tumma resigned effective November 4, 2026. Manohar Mollama has been appointed as the new Company Secretary effective November 5, 2026.
SMS Pharmaceuticals Q2 FY27 Results: Net Profit ₹39.9 Cr, Up 57.7% YoY
SMS Pharmaceuticals Ltd reported revenue from operations of ₹316.1 Cr (+30.4% YoY) and net profit of ₹39.9 Cr (+57.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹39.9 Cr · +57.7% YoY
SMS Pharmaceuticals Legal & Regulatory
SMS Pharmaceuticals received an Income Tax appellate order under Section 250 dismissing its appeal for AY 2018-19. The company says there is no material impact and is reviewing next steps.
- Value
- ₹0.40 Cr
SMS Pharmaceuticals Legal & Regulatory
SMS Pharmaceuticals disclosed that the CIT(Appeals) dismissed its appeal against a ₹7.19 Crore income tax assessment for AY 2018-19. The company is reviewing the order and expects no material impact.
- Value
- ₹7.19 Cr
SMS Pharmaceuticals Legal & Regulatory
SMS Pharmaceuticals received an Income Tax appellate order allowing its appeal for AY 2023-24. The outstanding tax demand of Rs.45.63 Crore, including interest, stands vacated.
- Value
- ₹45.63 Cr